Protagonist Therapeutics Inc (NASDAQ:PTGX) Director Bryan Giraudo bought 10,000 shares of the stock in a transaction that occurred on Wednesday, May 16th. The shares were purchased at an average cost of $6.46 per share, with a total value of $64,600.00. Following the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at $64,600. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
NASDAQ:PTGX traded up $0.01 during trading hours on Friday, reaching $6.00. The company had a trading volume of 278,017 shares, compared to its average volume of 205,703. The stock has a market capitalization of $127.22 million, a price-to-earnings ratio of -2.87 and a beta of 3.54. Protagonist Therapeutics Inc has a twelve month low of $5.50 and a twelve month high of $23.97.
Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings results on Wednesday, May 9th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). The business had revenue of $10.78 million for the quarter, compared to analyst estimates of $10.70 million. research analysts forecast that Protagonist Therapeutics Inc will post -0.98 EPS for the current year.
A number of brokerages recently weighed in on PTGX. Zacks Investment Research raised shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $26.00 target price for the company in a research note on Tuesday, March 13th. BMO Capital Markets reissued an “outperform” rating and set a $13.00 target price (down previously from $42.00) on shares of Protagonist Therapeutics in a research note on Monday, March 26th. They noted that the move was a valuation call. BidaskClub raised shares of Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 3rd. Finally, Stifel Nicolaus started coverage on shares of Protagonist Therapeutics in a report on Monday, January 29th. They issued a “buy” rating and a $32.00 price target for the company. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. Protagonist Therapeutics currently has a consensus rating of “Hold” and an average target price of $26.75.
A number of large investors have recently bought and sold shares of PTGX. Farallon Capital Management LLC acquired a new stake in Protagonist Therapeutics in the fourth quarter worth $18,720,000. First Manhattan Co. grew its holdings in Protagonist Therapeutics by 2,408.2% in the fourth quarter. First Manhattan Co. now owns 416,364 shares of the company’s stock worth $8,660,000 after purchasing an additional 399,764 shares during the period. BVF Inc. IL acquired a new stake in Protagonist Therapeutics in the fourth quarter worth $6,118,000. BlackRock Inc. grew its holdings in Protagonist Therapeutics by 39.0% in the first quarter. BlackRock Inc. now owns 687,160 shares of the company’s stock worth $5,904,000 after purchasing an additional 192,632 shares during the period. Finally, AWM Investment Company Inc. acquired a new stake in Protagonist Therapeutics in the fourth quarter worth $3,686,000. Institutional investors and hedge funds own 56.00% of the company’s stock.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.